Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial

Background The phase II NEOMUN trial was conducted to investigate the therapeutic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we report the final efficacy, safety, and long-term survival results.Methods Patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Albrecht Stenzinger, Dirk Jäger, Michael Thomas, Hauke Winter, Helge Bischoff, Uwe Haberkorn, Felix Herth, Pornpimol Charoentong, Petros Christopoulos, Rajkumar Savai, Laura V Klotz, Raffaella Griffo, Martin E Eichhorn, Florian Eichhorn, Benedikt Niedermaier, Philip Baum, Michael Allgäuer, Marc A Schneider, Claus-Peter Heußel, Maria Paula Roberti, Inka Zoernig
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e011874.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items